Market Place
Sourcing Support
All News #Library
Sciences
Femasys Secures CPT Code for FemaSeed
23 Feb 2026 //
GLOBENEWSWIRE
Femasys Gets FDA Clearance For Next-Gen Femvue Diagnostic Device
18 Dec 2025 //
GLOBENEWSWIRE
Femasys, Medical Electronic Systems Launch Femsperm™ Kit
22 Sep 2025 //
GLOBENEWSWIRE
Femasys Launches New Insemination Prep Kit in FemSperm™ Line
11 Sep 2025 //
GLOBENEWSWIRE
Femasys Gets FemBloc® Birth Control Approval in New Zealand
08 Sep 2025 //
GLOBENEWSWIRE
Femasys Launch FemSperm Kit to Boost FemaSeed Fertility Platform
21 Aug 2025 //
GLOBENEWSWIRE
Femasys Gets UK Approval for FemBloc Birth Control
20 Aug 2025 //
GLOBENEWSWIRE
FemBloc Gets EU Nod as First Non-Surgical Birth Control Option
25 Jun 2025 //
GLOBENEWSWIRE
Femasys Partners With Carolinas Fertility to Offer FemaSeed
11 Jun 2025 //
GLOBENEWSWIRE
Femasys Announces 2024 Financial Results and Corporate Update
27 Mar 2025 //
GLOBENEWSWIRE
Femasys Announces Positive Safety and Efficacy Results from FemBl
25 Feb 2025 //
GLOBENEWSWIRE
Femasys Announces Israeli Approvals for FemaSeed® & 2 Diagnostic
04 Feb 2025 //
GLOBENEWSWIRE
Femasys Granted Two European Patents For FemBloc Birth Control
30 Jan 2025 //
GLOBENEWSWIRE
Femasys Partners with Boston IVF for FemaSeed Offering
30 Oct 2024 //
GLOBENEWSWIRE
Femasys To Exhibit At ASRM 2024 And Join KEEPR Education Program
10 Oct 2024 //
GLOBENEWSWIRE
Femasys To Participate In Maxim Healthcare Virtual Summit
08 Oct 2024 //
GLOBENEWSWIRE
Femasys Gets Second Order from Spain for FemaSeed®
02 Oct 2024 //
GLOBENEWSWIRE
Femasys To Exhibit At Canadian Fertility Society Meeting
05 Sep 2024 //
GLOBENEWSWIRE
Femasys Inc. Obtains Medical Device Establishment License from Health Canada
31 Aug 2023 //
GLOBENEWSWIRE
Femasys€™ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis
03 May 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.